Diagens Biotechnology set for HK IPO

Diagens Biotechnology, strategic partner of Tencent (0700), plans to begin trading on the Hong Kong exchange, and the filing was approved by the China Securities Regulatory Commission on Monday. 

According to the filing, Diagens Biotechnology plans to issue no more than 31.004 million shares.

Diagens Biotechnology, founded in 2016, is a leading company in the field of medical imaging artificial intelligence (AI) and intelligent equipment, mainland media reported. 

The number and value of successful bids of Diagens Biotechnology in 2025 increased significantly compared to 2024, indicating strong growth in its full-year performance, as shown by public data. 

As one of the nation’s “little giant” enterprises,  Diagens Biotechnology has spent over 100 million yuan on AI research and development, computing power, and intelligent manufacturing, further solidifying its competitiveness in the field of medical imaging AI and intelligent equipment.

According to the official website of Diagens Biotechnology, Tencent rolled out the latest intelligent pre-annotation function based on Diagens’ iMed MaaS Platform at the Annual Ecological Cooperation Conference of Diagens last month.

Such indicates that the in-depth cooperation between Diagens and Tencent has fully stepped into a new phase centered on the large-scale deployment of innovative functions, evolving from the initial strategic alliance and ecological co-construction to co-shaping a grand blueprint for medical imaging AI.